PIK3CA and familial pancreatic carcinoma: Further, several molecular profiling studies revealed that up to 48% of pancreatic cancers harbor therapeutically relevant genomic alterations, such as ERBB2, MET, FGFR1, CDK6, PIK3R3, and PIK3CA at low individual patient prevalence (3, 8, 10).